UCB agreed to acquire Candid Therapeutics for $2 billion upfront, betting on Candid’s bispecific antibody portfolio for autoimmune diseases. The buyout includes antibody assets Candid licensed from China-based biotechs, which UCB frames as part of a “next wave” for immunological conditions. UCB’s move accelerates its exposure to next-generation T-cell engager and bispecific modalities at a time when competition for differentiation is intensifying among large and mid-sized immunology players. For Candid partners and licensors, the transaction is a liquidity event and a validation of technology scouting models that pull assets from external innovation sources. The report also flags that the deal could include strategic optionality beyond the base consideration, with details tied to the transaction structure and integration plans. Overall, it is a direct consolidation bet on engineered antibody platforms to expand autoimmune pipelines and strengthen late-stage execution capacity.